China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Gap Down – Time to Sell?

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) gapped down prior to trading on Tuesday . The stock had previously closed at $6.4650, but opened at $5.60. China SXT Pharmaceuticals shares last traded at $5.4010, with a volume of 69,414 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Price Performance

The company’s 50-day simple moving average is $145.01 and its 200 day simple moving average is $200.74.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings data on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million for the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

An institutional investor recently bought a new position in China SXT Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 48,759 shares of the company’s stock, valued at approximately $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.